A novel orally active gonadotropin‐releasing hormone antagonist, relugolix, is a potential substitute for injectable GnRH antagonists in controlled ovarian stimulation in assisted reproductive technology

PURPOSE: To evaluate the efficacy of an oral gonadotropin‐releasing hormone antagonist (GnRH Ant), relugolix (R), for assisted reproductive technology (ART). METHODS: We enrolled women undergoing ART using a GnRH Ant for controlled ovarian stimulation. We compared R; 20 mg/day with cetrorelix acetat...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamada, Michiko, Horikawa, Michiharu, Ensaka, Chie, Enomoto, Megumi, Ishii, Rena, Toriumi, Rena, Tachibana, Naoyuki, Taketani, Yuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8658872/
https://www.ncbi.nlm.nih.gov/pubmed/34938148
http://dx.doi.org/10.1002/rmb2.12424

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8658872/
https://www.ncbi.nlm.nih.gov/pubmed/34938148
http://dx.doi.org/10.1002/rmb2.12424

Ejemplares similares